Table 4. The clinical and tumor characteristics between patients with TDs (P value compared to TD =1).
| Characteristics | All TDs+ patients | TD =1 | TDs =2–4 | P value | TDs ≥5 | P value |
|---|---|---|---|---|---|---|
| Sex | 0.609 | 0.598 | ||||
| Female | 1,607 (49.25%) | 873 (49.43%) | 557 (48.39%) | 177 (51.16%) | ||
| Male | 1,656 (50.75%) | 893 (50.57%) | 594 (51.61%) | 169 (48.84%) | ||
| Race | 0.045 | 0.045 | ||||
| White | 2,511 (76.95%) | 1,333 (75.48%) | 905 (78.63%) | 273 (78.90) | ||
| Black | 388 (11.89%) | 238 (13.48%) | 120 (10.43%) | 30 (8.61) | ||
| Other | 364 (11.16%) | 195 (11.04%) | 126 (10.95%) | 43 (12.3) | ||
| Age at diagnosis, years | 0.403 | 0.171 | ||||
| <65 | 1,519 (46.55%) | 804 (45.53%) | 543 (47.18%) | 172 (49.71%) | ||
| ≥65 | 1,744 (53.45%) | 962 (54.47%) | 608 (52.82%) | 174 (50.29%) | ||
| Tumor location | 0.003 | 0.088 | ||||
| Left | 1,782 (54.61%) | 919 (52.04%) | 665 (57.78%) | 198 (57.23%) | ||
| Right | 1,481 (45.39%) | 847 (47.96%) | 486 (42.22%) | 148 (42.77%) | ||
| Histological grade | <0.001 | <0.001 | ||||
| Well | 166 (5.087%) | 72 (4.077%) | 69 (5.995%) | 25 (7.225%) | ||
| Moderately | 2,335 (71.56%) | 1,326 (75.08%) | 792 (68.81%) | 217 (62.72%) | ||
| Poorly | 626 (19.18%) | 318 (18.01%) | 224 (19.46%) | 84 (24.28%) | ||
| Undifferentiated | 136 (4.168%) | 50 (2.831%) | 66 (5.734%) | 20 (5.780%) | ||
| Pathological type | 0.601 | 0.013 | ||||
| Adenocarcinoma | 2,948 (90.35%) | 1,607 (91.00%) | 1,044 (90.70%) | 297 (85.84%) | ||
| Mucinous | 271 (8.305%) | 139 (7.871%) | 89 (7.732%) | 43 (12.43%) | ||
| Signet-ring cell carcinoma | 44 (1.348%) | 20 (1.133%) | 18 (1.564%) | 6 (1.736%) | ||
| AJCC 8th stage | <0.001 | <0.001 | ||||
| IIIA | 267 (8.183%) | 186 (10.53%) | 66 (5.734%) | 15 (4.335%) | ||
| IIIB | 2,278 (69.81%) | 1,292 (73.16%) | 786 (68.29%) | 200 (57.80%) | ||
| IIIC | 718 (22.00%) | 288 (16.31%) | 299 (25.98%) | 131 (37.86%) | ||
| AJCC 8th T | <0.001 | <0.001 | ||||
| T1 | 78 (2.390%) | 59 (3.341%) | 16 (1.390%) | 3 (0.86%) | ||
| T2 | 233 (7.141%) | 154 (8.720%) | 65 (5.647%) | 14 (4.046%) | ||
| T3 | 2,154 (66.01%) | 1,185 (67.10%) | 756 (65.68%) | 213 (61.56%) | ||
| T4 | 798 (24.46%) | 368 (20.84%) | 314 (27.28%) | 116 (33.53%) | ||
| AJCC 8th N | <0.001 | <0.001 | ||||
| N1 | 2,372 (72.69%) | 1,411 (79.90%) | 775 (67.33%) | 186 (53.76%) | ||
| N2 | 891 (27.31%) | 355 (20.10%) | 376 (32.67%) | 160 (46.24%) | ||
| Chemotherapy | 0.065 | 0.342 | ||||
| None/unknown | 1,280 (39.23%) | 709 (40.15%) | 422 (36.66%) | 149 (43.06%) | ||
| Yes | 1,983 (60.77%) | 1,057 (59.85%) | 729 (63.34%) | 197 (56.94%) |
TD, tumor deposits.